• GT Biopharma posted a Q2 operating loss of $4.5 million, widening from $1.5 million a year earlier.
• Net loss was $4.5 million, narrowing from $30.2 million in the prior-year quarter due to a $28.7 million non-cash Greenshoe Rights liability then.
• R&D expenses climbed to $1.1 million from $0.4 million, driven by higher materials and production costs.
• SG&A expenses rose to $3.4 million from $1.1 million on higher marketing spend, with legal and consulting fees also up.
• Cash and cash equivalents were about $5.1 million at June 30, 2026, seen funding operations through Q4 2026; Phase 1 updates for GTB-3650 and GTB-5550 are expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED9809957) on August 14, 2026, and is solely responsible for the information contained therein.